Aileron Therapeutics Reports Third Quarter 2017 Financial Results Thu, 09 Nov 2017 21:18:19 +0000 Company continues to advance clinical trials of lead product candidate ALRN-6924 in PTCL and AML/MDS. Two abstracts selected for oral presentations at American Society of Hematology Annual Meeting, highlighting ...
Boston biotech developing obesity drug pulls down $120M in IPO Thu, 05 Oct 2017 10:40:14 +0000 A 9-year-old biotech company headquartered in Boston’s Back Bay, Rhythm Pharmaceuticals Inc. has become the fourth local drugmaker to go public this year, raising $120 million in an upsized public offering. Rhythm, which has 15 employees based in a 6,830-square-foot office at 500 Boylston St., sold 7 million shares for $17 each, beating the range it floated in a federal filing just a couple weeks ago of $14-$16. It’s the second-biggest IPO for a Boston-area biotech in what’s so far a slow year, with only Cambridge-based Akcea Therapeutics (AKCA) raising more, with a $144 million IPO in July .
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.